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Abstract
Background: Recent hypotheses have suggested the pathophysiological role of catecholamines in the evolution of
the Takotsubo syndrome (TTS). The extent of cardiac and circulatory compromise dictates the use of some form of
supportive therapy. This study was designed to investigate the clinical outcomes associated with catecholamine use
in TTS patients.
Methods: Our institutional database constituted a collective of 114 patients diagnosed with TTS between 2003 and
2015. The study-patients were subsequently classified into two groups based on the need for catecholamine
support during hospital stay (catecholamine group n = 93; 81%, non-catecholamine group = 21; 19%). The primary
end-point of our study was all-cause mortality.
Results: Patients receiving catecholamine support showed higher grades of circulatory and cardiac compromise
(left ventricular ejection fraction (LVEF) 39.6% vs. 32.7%, p-value < 0.01) and the course of disease was often
complicated by the occurrence of different TTS-associated complications. The in-hospital mortality (3.2% vs. 28.5%,
p < 0.01), 30-day mortality (17.2% vs. 51.4%, p < 0.01) as well as long-term mortality (38.7% vs. 80.9%, p < 0.01) was
significantly higher in the group of patients receiving catecholamine support. A multivariate Cox regression analysis
attributed EF ≤ 35% (HR 3.6, 95% CI 1.6–8.1; p < 0.01) and use of positive inotropic agents (HR 2.2, 95% CI 1.0–4.8;
p 0.04) as independent predictors of the adverse outcome.
Conclusion: Rates of in-hospital events and short- as well as long-term mortality were significantly higher in TTS
patients receiving catecholamine support as compared to the other study-patients. These results need further
evaluation in pre-clinical and clinical trials to determine if external catecholamines contribute to an adverse clinical
outcome already compromised by the initial insult.
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Background
The Takotsubo Syndrome (TTS) is as an acute and
usually reversible from of heart failure characterized by
a transient dysfunction of the left ventricle [1, 2]. The
TTS patient presents with clinical features such as acute
chest pain and dyspnea, bearing some similarity to the
patient presenting with an acute myocardial infarction
or an acute coronary syndrome (ACS) [3]. An increase
in cardiac troponin and creatine kinase levels as well as
electrocardiogram (ECG) changes on admission suggest-
ing ST-segment elevation in precordial leads adds to the
confusion in early diagnosis. The absence of significant
coronary stenosis on coronary angiography, which could
correlate with this presentation, and the history of an
emotional or physical trigger, leads to the potential
diagnosis of TTS [3, 4]. This non-ischemic syndrome
has also alternatively been labeled as a stress- or stress-
induced cardiomyopathy, an apical ballooning syndrome,
or ‘broken heart syndrome’ [4–8].
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The classical pattern of left ventricular (LV) morphology
in TTS, present in almost 50–80% of all patients, is the
apical variant, which is characterized by apical ballooning
of the LV at end-systole. Other morphological presenta-
tions include those defined by a predominantly hypoki-
netic circumferential base (inverted Takotsubo variant), or
a hypokinetic circumferential mid ventricle (mid LV
variant), or demonstrating focal variations [9–13].
The pathophysiology of TTS has been well-debated,
however is still poorly described. The influence of an
acute catecholaminergic surge contributing to some
form of myocardial stunning has been hypothesized by
several researchers [14]. Stressful triggers could poten-
tially contribute to an increased hypothalamic-pituitary-
adrenal axis (HPA) gain and catecholamine release. This
resulting catecholamine surge possibly directs a patho-
logical response from the cardiovascular as well the
sympathetic nervous system and serves as the basis for
the evolution of TTS [15, 16].
This interesting correlate, naturally, has far-reaching
clinical implications. The therapeutic use of catechol-
amines has been routinely advocated in cases of circula-
tory compromise, however, its use in the setting of TTS
could have potential drawbacks. Extrapolating this
thought, our study attempts to explore the hither to
poorly understood pathophysiological mechanisms
involved in the TTS and determine if external catechol-
amines contribute to an adverse clinical outcome already
compromised by the initial insult.
Methods
Study design and population characteristics
This study incorporated a population subset derived
from a patient collective diagnosed with TTS at the
University Medical Centre Mannheim, Germany be-
tween January 2003 and September 2015. A total of 114
patients were included consecutively to this mono-
centric and observational study designed for retrospect-
ive data analysis. All these patients were essentially diag-
nosed with the TTS on hospital admission, and their
presenting features met the conditions set out by the
modified Mayo Clinic Criteria [17]. These criteria essen-
tially highlight the transient wall motion abnormality in
the LV mid-segments with or without apical involve-
ment; describe regional wall motion abnormalities that
extend beyond a single epicardial vascular distribution;
and define an event that occurs frequently, but not
always in the wake of a successful trigger. Additionally,
these salient criteria mandate the effective rule-out of
occlusive coronary disease; focuses on the appearance of
new ECG pathologies, which mimic ACS or modest
elevations in cardiac troponin levels; and underlines the
prerequisite absence of diseases like pheochromocytoma
and myocarditis in the patient.
Patients with co-existing occlusive coronary artery
disease as well as those exhibiting wall-motion abnor-
malities corresponding to any single coronary vessel
territory were excluded from this study. A total of 18 pa-
tients with uncertain TTS, with no record of coronary
angiography or echocardiography results, were excluded
from this study. The relevant clinical data of each study-
patient was ascertained and compiled in a database with
significant aspects of their medical history, laboratory
work-up and medical/surgical therapy efficiently
earmarked for future reference. Additional parameters
outlined for evaluation included duration of hospital
stay, need for monitoring and care in the ICU (intensive
care unit), use of invasive or non-invasive ventilation,
inotropic support, temporary pacing, and demand for
renal replacement therapy. Essential diagnostic workup
including a routine ECG, echocardiography (to evaluate
LV, RV function and wall-motion abnormalities), and a
coronary and LV angiography (to rule out occlusive
coronary artery disease) was performed on all patients.
A consolidated review of this data was conducted by two
independent cardiologists and once the diagnosis of TTS
was reaffirmed, the study-patients were subsequently
classified into two groups based on the need for cat-
echolamine support during hospital stay. A consortium
diagram to explain the population recruitment has been
outlined in Fig. 1.
The primary end-point of our study was all-cause mor-
tality as assessed by chart review and/or telephonic review.
If medical records, treating physicians or relatives were
unable to provide further information concerning the
circumstances of death, it was defined as death due to
unknown cause.
The research conduct corresponded to the principles
outlined in the declaration of Helsinki and was approved
by the medical ethics committee of the Faculty of Medicine
in Mannheim, University of Heidelberg, Germany.
Statistics
Statistical analyses were performed using SPSS Version
22 (SPSS Inc., Chicago, Illinois). Data is presented here
as means ± SD for continuous variables with a normal
distribution, median (interquartile range) for continuous
variables with a non-normal distribution, and as fre-
quency (%) for categorical variables. The Kolmogorov–
Smirnov test was used to assess normal distribution.
Student’s t-test and the Mann–Whitney U-test were
used to compare continuous variables with normal and
non-normal distributions, respectively. The chi-squared-
test or Fisher’s exact test was used to compare categor-
ical variables. The log-rank test was used to compare the
survival curves between the two patient groups classified
as per catecholamine use. p-values < 0.10 on univariate
analysis were further evaluated via the Cox multivariate
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regression to define independent risk factors for the
respective end-point. A two-tailed p-value of < 0.05 was
considered statistically significant.
Results
Baseline characteristics
The baseline characteristics of the 114 patients included
in this study have been referenced in Table 1.
A detailed analysis of available data revealed an insig-
nificant demographic distribution, with age and gender
variables expressed almost similarly in both patient
groups. Chest pain was interestingly more pronounced
in the hemodynamically stable patient (55.9%, n = 52, vs.
28.5%, n = 6, p = 0.03) as compared to those requiring
some form of catecholamine support. The clinical pa-
rameters used to ascertain patient status, such as systolic
blood pressure (134.96 ± 28.41 mmHg vs. 116.25 ±
42.3 mmHg, p = 0.01) and heart rate (98.1 ± 27.6 bpm vs.
110.9 ± 22.7 bpm, p = 0.03), expectedly showed variation
between the two groups, wherein lower blood pressure
values and mild tachycardia was frequently observed
among patients requiring catecholamine support.
Diagnostic parameters
The initial diagnostic work-up, detailed with an
electrocardiogram, suggested catecholamine-support-
free patients recorded significantly longer QTc-Interval’s
as opposed to the hemodynamically unstable catechol-
amine therapy-dependent patient (484.49 ± 50.83 ms vs.
455.30 ± 52.82 ms, p = 0.02). Other diagnostic parame-
ters like echocardiographic estimates of left-ventricular
ejection fraction revealed a comparatively lower degree
of compromise in cardiac function among patients not
requiring external catecholamines (index LVEF measure-
ments 39.67 ± 9.12% vs. 32.76 ± 9.09%, p < 0.01). Simi-
larly, lower index troponin-I levels were documented in
this group (3.20 ± 4.41 U/l vs. 6.57 ± 8.46 U/l, p = 0.01).
Right ventricular involvement was less pronounced in
the non-catecholamine support patient-group (18.2%,
n = 17 vs. 42.85%, n = 9, p = 0.02).
In-hospital outcome
Data detailing in-hospital events and treatment strategies
adopted for our study population suggested that patients
suffering from hemodynamic compromise and requiring
catecholamine support had a significantly increased inci-
dence of life-threatening arrhythmias (33.3%, n = 7 vs.
6.4%, n = 6, p < 0.01) as well as cardiogenic shock (85.7%,
n = 18 vs. 4.3%, n = 4, p < 0.01) and often required admis-
sion to an intensive care unit with longer stays (9.5 ±
11.3 days vs. 3.2 ± 3.5 days, p < 0.01). Rates of in-hospital
death were higher among patients receiving catechol-
amine support (28.5%, n = 6 vs. 3.2%, n = 3, p < 0.01).
Non-invasive positive pressure ventilation, endotracheal
intubation and cardiopulmonary resuscitation proce-
dures were practised significantly more often in patients
constituting this group, Table 2.
Long-term follow-up
TTS patients receiving catecholamine support registered
significantly higher 30-day mortality rates as compared
to the clinically stable patient (57.14%, n = 12 vs.17.2%,
n = 16, p < 0.01). Furthermore, these patients showed an
ongoing increased risk of death beyond the first 30-days
Fig. 1 Flow Diagram of study
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after hospital admission resulting in considerably
higher long-term mortality-rates (80.95%, n = 17 vs.
38.70%, n = 36, p < 0.01); Table 3, Fig. 2. In a Cox univar-
iate analysis EF ≤35% (HR 4.8, 95% CI 2.2–104; p < 0.01),
male gender (HR 2.6, 95% CI 1.2–5.7; p 0.01) and use
of positive inotropic agents (HR 3.9, 95% CI 1.9–7.9;
p < 0.01) were associated with an adverse outcome. In
comparison, a multivariate Cox regression analysis at-
tributed EF ≤ 35% (HR 3.6, 95% CI 1.6–8.1; p < 0.01)
and use of positive inotropic agents (HR 2.2, 95% CI
1.0–4.8; p 0.04) as independent predictors of the
adverse outcome, Table 4. The various causes of death
have been illustrated in Table 5.
Discussion
The principal foundation of this study was to determine the
role and influence of catecholamine therapy in the treat-
ment of the hemodynamically unstable TTS patient. At the
outset, patients receiving catecholamine support showed
Table 1 Baseline characteristics of 114 patients initially presenting
with TTC
Variables No catecholamines
(n = 93)
catecholamines
(n = 21)
p value*
Demographics
Age, mean ± SD 67.65 ± 11.00 65.00 ± 12.30 0.33
Male, n (%) 13 (13.97) 6 (28.57) 0.11
Symptoms, n (%)
Dyspnoe 34 (36.55) 9 (42.85) 0.62
Chest pain 52 (55.91) 6 (28.57) 0.03
Clinic parameter
Systolic BP, mmHg 134.96 ± 28.41 116.25 ± 42.32 0.01
Diastolic BP, mmHg 78.41 ± 13.67 66.55 ± 31.22 0.03
Heart rate, bpm 98.17 ± 27.64 110.95 ± 22.79 0.05
ECG Data, n (%)
ST-segment elevation 27 (29.03) 7 (33.33) 0.79
Inversed T-Waves 83 (89.24) 19 (90.47) 0.74
PQ-interval 160.67 ± 27.97 160.00 ± 34.38 0.92
QTc (ms), mean ± SD 484.49 ± 50.83 455.30 ± 52.82 0.02
Stress factor, n (%)
Emotional sress 28 (30.10) 2 (9.52) 0.05
Physical stress 50 (53.76) 14 (66.66) 0.33
Laboratory values, mean ± SD
Troponin I (U/L) 3.20 ± 4.41 6.57 ± 8.46 0.01
Creatine
phosphatkinase (U/L)
721.11 ± 2900.64 323.74 ± 469.71 0.55
CKMB 37.44 ± 65.08 31.00 ± 23.56 0.77
C-Reactive protein (mg/
l)
42.63 ± 64.25 80.30 ± 126.15 0.06
Hemoglobin 12.10 ± 1.99 12.29 ± 2.08 0.70
Creatinine (mg/dl) 1.14 ± 0.76 1.19 ± 0.50 0.79
GFR < 60 ml/min 25 (26.88) 7 (33.33) 0.59
Echocardiography data, n (%)
LV EF % 39.67 ± 9.12 32.76 ± 9.09 < 0.01
Follow-up LV EF % 55.23 ± 7.54 48.63 ± 14.90 < 0.01
Apical ballooning 64 (68.81) 18 (85.71) 0.15
Mitral regurgation 50 (53.76) 10 (47.61) 0.63
Tricspid regurgation 42 (45.16) 7 (33.33) 0.46
RV-Involvement 17 (18.27) 9 (42.85) 0.02
Medical history, n (%)
Smoking 30 (32.25) 6 (28.57) 0.80
Diabetes mellitus 22 (23.65) 4 (19.04) 0.64
Obesity (BMI > 25 kg/
m2)
27 (29.03) 4 (19.04) 0.75
Hypertension 54 (58.06) 12 (57.14) 1.00
COPD 19 (20.43) 7 (33.33) 0.25
Atrial fibrillation 15 (16.12) 6 (28.57) 0.21
Coronary artery disease 16 (17.20) 6 (28.57) 0.23
Table 1 Baseline characteristics of 114 patients initially presenting
with TTC (Continued)
Variables No catecholamines
(n = 93)
catecholamines
(n = 21)
p value*
History of malignancy 13 (13.97) 3 (14.28) 0.97
Drugs on admission, n (%)
Beta-blocker 32 (34.40) 3 (14.28) 0.06
ACE inhibitor 30 (32.25) 5 (23.80) 0.45
ASS 24 (25.80) 5 (23.80) 0.87
Anticoagulation 7 (7.52) 0 (0) 0.19
*p values for the comparison between group 1 and group 2; SD Standard
deviation, ECG Electrocardiogram, EF Ejection fraction, BMI body-mass-index,
COPD Chronic obstructive pulmonary disease,
ACE Angiotensin-convetring-enzyme
EFhochversusnichthoch*Katecholaminpflichtigkeit: 0.000
The bolded indication highlight significant values
Table 2 In-hospital events and treatment strategy
Variables No catecholamines
(n = 93)
catecholamines
(n = 21)
p value*
Life-threatening arrhythmia 6 (6.45) 7 (33.33) < 0.01
NPPV and intubation 21 (22.5) 18 (85.7) < 0.01
Resuscitation 3 (3.22) 6 (28.57) < 0.01
Defibrillator-Implantation 1 (1.0) 1 (4.7) 0.33
VA-ECMO 0 (0) 1 (4.7) 0.18
Admission to ICU, length
of stay
3.24 ± 3.59 9.57 ± 11.32 < 0.01
In-hospital death 3 (3.2) 6 (28.5) < 0.01
Thromboembolic events 10 (10.75) 4 (19.04) 0.29
Acquired Long QTs 61 (65.59) 12 (57.14) 0.41
Cardiogenic Shock 4 (4.30) 18 (85.71) < 0.01
*p values for the comparison between no catecholamines and catecholamines;
NPPV Noninvasive positive pressure ventilation, VA-ECMO Veno-arterial
extracorporal membrane oxygenation, ICU Intermediate care unit
The bolded indication highlight significant values
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higher degrees of circulatory and cardiac compromise,
and the course of disease was often complicated by
the occurrence of different TTS-associated complications.
This group of patients also demonstrated poorer in-
hospital outcomes and had higher long-term mortality
rates as compared to the group of patients not receiving
any catecholamine support therapy. It could therefore be
inferred that circulatory support in the form of catechol-
amines entails a poorer outcome for the TTS patient. A
pertinent question arises when debating the role of
catecholamines exacerbating the mortality risk in such a
clinical scenario solely on the basis of the pathophysiology
of the syndrome. All patients, irrelevant of diagnosis, re-
quiring catecholamine support constitute a clinically com-
promised group, however, do TTS patients in circulatory
or cardiac shock suffer from additional drawbacks due to
this line of management? Our results indicate that con-
temporary circulatory support drugs like catecholamines
additionally exacerbates the risk of mortality in a TTS
patient. This study is probably the first of many to follow,
that has attempted to express this distinct correlation.
Although, many studies have attributed some form of
catecholamine toxicity leading to the pathophysiological
evolution of TTS, we shall explore this line of discussion
further, considering the potential impact on current treat-
ment strategies.
A detailed research of recently published literature
highlights the several hypotheses which have been
postulated to explain the pathogenesis of TTS. These
mechanisms essentially entail the possibility of coronary
microvascular dysfunction, coronary artery spasm,
catecholamine-induced myocardial stunning, acute LV
outflow obstruction, acute increased ventricular after-
load, myocardial microinfarction or abnormalities in car-
diac fatty acid metabolism influencing the development
of TTS [15].
A common link serving these several theories can
be construed with the consistent demonstration of
some form of microvascular dysfunction among all
TTS patients. The research work conducted by
Uchida et al. could successfully exhibit the presence
of extensive endothelial apoptosis in myocardial biopsies
[18] while Afonso et al. demonstrated circulatory distur-
bances in myocardial contrast echocardiography [19].
Table 3 Outcome (mortality) in TTS patients
Variables No catecholamines
(n = 93)
catecholamines
(n = 21)
Relative risk
(95% CI)
p value *
In-hospital mortality 3 (3.22) 6 (28.57) (1.0–6.5) < 0.01
30-day mortality 3 (2.15) 6 (28.57) (1.0–6.5) < 0.01
1-year mortality 6 (6.45) 8 (38.09) (1.1–3.7) < 0.01
2-year mortality 11 (11.82) 10 (47.61) (1.1–2.5) < 0.01
3-year mortality 12 (12.90) 11 (52.38) (1.1–2.5) < 0.01
4-year mortality 18 (19.35) 11 (52.38) (1.0–1.9) < 0.01
Long-term mortality 20 (21.50) 13 (61.90) (1.1–2.0) < 0.01
*p values for the comparison between no catecholamines and catecholamines
Fig. 2 Log-rank and survival rates of patients treated and not
treated with catecholamines
Table 4 Multivariate analysis for the end point (all-cause mortality)
Univariate analysis Multivariate analysisa)
HR 95% CI P-value HR 95% CI P-value
Male 2.6 1.2–5.7 0.01 1.8 0.8–4.0 0.14
EF≤ 35% 4.8 2.2–104 < 0.01 3.6 1.6–8.1 < 0.01
Emotionalerstress 0.4 0.1–1.1 0.10
Inotropic drugs 3.9 1.9–7.9 < 0.01 2.2 1.0–4.8 0.04
Diabetes mellitus Typ II 1.0 0.7–1.4 0.81
Hypertension 0.9 0.7–1.2 0.64
Apical ballooning 1.1 0.8–1.4 0.39
History of cancer 1.7 0.7–4.2 0.21
Smoking 0.7 0.3–1.6 0.49
HR hazard ratio, EF ejection fraction, CRP c-reactive protein, GFR glomerular
filtration rate
aOnly the following variables with significant effects in univariate analysis were
analyzed by multivariate Cox regression: Male, EF ≤ 35%, Inotropic drugs
The bolded indication highlight significant values
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Abnormalities associated with endothelium dependent
vasodilatation, excessive vasoconstriction and impairment
of myocardial perfusion have been associated with coron-
ary microvascular dysfunction seen in TTS patients [20].
The additional demonstration of regional contraction
band necrosis, inflammatory cell inflammation and local-
ised fibrosis, all attributed to direct catecholamine toxicity,
further corroborates this theory [17, 21]. Interesting
results interpreted from the research of Morel et al.
suggested that an increase in C-reactive protein levels and
white blood cell counts corresponded to increased levels
of catecholamines in TTS patients [22]. The raised levels
could in theory initiate a systemic inflammation mediated
by cytokines like TNF-alpha and interleukin-6, explaining
the observation of myocardial oedema in cardiac MRI
[23]. In animal models of TTS, as prepared by Paur et al.,
the use of high bolus doses of catecholamines has simu-
lated LV apical ballooning [24]. Additional studies by
Wittstein et al., proving increased levels of circulating
catecholamines in TTS patients as compared to those
with myocardial infarction, as well as the theory of
“stimulus trafficking” (involving a switch in intracellu-
lar signal trafficking from Gs protein to Gi protein)
proposed by Lyon et al. have all given credence to
the hypothesised pathogenic role of catecholamines in
the development of TTS [24–26].
Although, these above-mentioned studies effectively
hint at a definitive pathophysiological role played by cat-
echolamines in the evolution of the syndrome, they fall
short of explaining the potential effects of exogenous
catecholamines in exacerbating a case of existing TTS.
A detailed analysis of our published research in this
respect revealed that in-hospital events as well as short-
and long-term mortality rates among TTS patients diag-
nosed with a significantly reduced LVEF on admission
were significantly higher [27, 28]. We also showed that
rates of in-hospital events and short- as well as long-
term mortality rates were significantly higher in TTS
patients suffering from arrhythmias such as atrial fibril-
lation [29, 30]. Although, such clinical scenarios do place
the TTS patient at the worse end of the spectrum, it
does not effectively explain the additional deleterious
effects observed when patients received exogenous cate-
cholamines as a form of therapy. An extrapolation of
our data suggests reduced LVEF and use of positive
inotropic agents as independent predictors of adverse
outcome. A plausible explanation for this observation
is perhaps the reactivation of catecholamine receptors
or their downstream molecular pathways in the acute
phase of TTS, which exacerbates the effects of the
syndrome.
Our study has significant clinical implications. The
essential role of catecholamines in the treatment of
circulatory compromise has been consistently validated
in the past, however, its use in TTS patients is now
certainly questionable. Considering the pathophysiology
of the syndrome, it would be pertinent to avoid any sort
of catecholamine therapy for such patients. The Heart
Failure Association of the European Society of Cardiology
has recommended the avoidance or withdrawal of
exogenous catecholamines as they could probably
prolong or exacerbate the acute phase of the
syndrome by activation of catecholamine receptors or
their downstream molecular pathways [31]. It is for
this reason that experts have suggested the early use
of left ventricular assist device (LVAD) or extracorporeal
membrane oxygenation (ECMO) as a bridge to recovery
in highly unstable patients. Although treatment with levo-
simendan in this scenario is controversial, the absence of
mechanical support may necessitate its use in certain
scenarios [15].
This study clearly highlights the pitfalls associated with
catecholamine use in patients suffering from circulatory
compromise. The observation that most patients did not
noticeably profit from this line of management and
consistently suffered from poorer clinical outcomes with
higher long-term mortality rates cements further
support to recently postulated hypotheses and current
recommendations for clinical management.
Study limitations
This study was limited by its single-center retrospective
observational study design, which included patients
admitted over the period of 13 years. There was insuffi-
cient data detailing the proposed limits and quantified
catecholamine doses used in these patients, furthermore,
preventing the definitive assessment of the prognostic
impact of different treatment strategies such as ECMO
and intra-aortic balloon pump (IABP).
Conclusion
This study equivocally suggests that TTS patients
receiving catecholamine therapy show higher grades
of circulatory and cardiac compromise, have poorer
Table 5 All-Cause of death
In-hospital mortality
1. Cardiac cause including cardiogenic shock and life-threatening
arrhythmia (n = 6)
2. Malignoma (n = 1)
3. Neurological cause (n = 2)
Out of hospital mortality
1. Cardiac cause including cardiogenic shock and life-threatening
arrhythmia (n = 4)
2. Malignoma (n = 6)
3. Sepsis (n = 4)
4. Kidney failure (n = 2)
5. Pulmonary cause (n = 2)
6. Unknown cause (n = 6)
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in-hospital outcomes and demonstrate higher long-
term mortality rates in comparison to patients not re-
ceiving any form of catecholamine support. Although,
these patients could in effect be suffering from a severe
form of TTS, the interplay between the several mecha-
nisms involved in the pathogenesis of this syndrome
dictates the planning of therapeutic strategies precluding
exogenous catecholamine use.
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